Preferences for Adjuvant Immunotherapy in Adults with Resected Stage III Melanoma-A Discrete Choice Experiment.

Ann Livingstone Kirsten Howard Alexander M Menzies Georgina V Long Martin R Stockler Rachael Lisa Morton

Published in: The patient (2023)

Almost three-quarters of respondents chose adjuvant immunotherapy over no adjuvant immunotherapy, preferring treatment that improved efficacy and safety. Findings may inform decisions about access to adjuvant immunotherapy following surgery for melanoma.

Keyphrases

early stage
minimally invasive
skin cancer